IJ
Therapeutic Areas
Neurophyxia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| 2-iminobiotin (2-IB) | Cerebral hypoxia-ischemia following Stroke | Phase IIb/III |
Leadership Team at Neurophyxia
CP
Cacha Peeters-Scholte, MD, PhD
Co-founder & Chief Scientific Officer
LG
Leo G. J. de Leede, PharmD, RPh, PhD
Chief Pharmaceutical Development Officer
DE
Drs. Elize van der Hoeven, PharmD
Chief Operation Officer
HT
Huibert Tjabbes
Co-founder & Safety Officer